Conversely, the aberrant upregulation of RUNX3 in metastatic cancer may be targeted therapeutically by small molecule inhibitors, such as the pyrrole-imidazole polyamide Chb-M’, benzodiazepine Ro5-3335, as well as 2-pyridyl benzimidazole AI-4-57 and derivatives [86,87,88,89]. Here, RUNX3 is linked to metastatic malignant neoplasm.